724424-43-5Relevant articles and documents
Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535
Duplantier, Allen J.,Dombroski, Mark A.,Subramanyam, Chakrapani,Beaulieu, Aimee M.,Chang, Shang-Poa,Gabel, Christopher A.,Jordan, Crystal,Kalgutkar, Amit S.,Kraus, Kenneth G.,Labasi, Jeff M.,Mussari, Christopher,Perregaux, David G.,Shepard, Rick,Taylor, Timothy J.,Trevena, Kristen A.,Whitney-Pickett, Carrie,Yoon, Kwansik
, p. 3708 - 3711 (2011/07/31)
High throughput screening (HTS) of our compound file provided an attractive lead compound with modest P2X7 receptor antagonist potency and high selectivity against a panel of receptors and channels, but also with high human plasma protein bindi
Combination therapies utilizing benzamide inhibitors of the P2X7 receptor
-
Page/Page column 40, (2010/02/15)
This invention provides methods of treatment of IL-1 mediated diseases comprising administering a pharmaceutically effective amount of a pharmaceutical agent selected from the group of sulfasalazine, a statin, a glucocorticoid agent, an inhibitor of p38 k
Methods for preparing P2X7 inhibitors
-
Page/Page column 16, (2010/02/15)
The present invention relates to the methods for preparing compounds of the formula I: or the pharmaceutically acceptable salts thereof, wherein R1, R2, R4, R10, and R11 have any of the values defined
Methods for preparing P2X7 inhibitors
-
Page/Page column 26-27, (2008/06/13)
The present invention relates to methods of preparing compounds of formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R4, and R7 have any of the values as defined in the specification. The
3-(3,5-DIOXO-4,5-DIHYDRO-3H-(1,2,4)TRIAZIN-2-YL)-BENZAMIDE DERIVATIVES AS P2X7-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
-
Page/Page column 60, (2008/06/13)
The present invention provides benzamide inhibitors of the P2X7 receptor of the formula (I), wherein R1 and R2 are as defined in claim 1. R3 is a nitrogen linked (C1-C10) heterocyclyl of fo